adminNHS to Roll Out Mounjaro for Weight Loss, But Full Access Could Take 12 Years
The NHS in England is preparing to introduce Mounjaro, a new weight-loss injection, but it may take up to 12 years before all eligible patients can access it, according to the National Institute for Health and Care Excellence (NICE). The treatment, set to be offered starting March 2025, will be available to people with obesity and related health conditions.
Mounjaro, developed by Eli Lilly, works by curbing appetite, helping users feel fuller for longer. Clinical trials have shown that patients using the drug can lose up to 20% of their body weight. However, concerns about the strain on the NHS—particularly General Practitioners (GPs)—mean that the rollout will be gradual, with only a limited number of patients able to access the drug initially.
Gradual Rollout, Starting with Specialist Clinics
Initially, the drug will be prescribed to people with a BMI of over 35 who also suffer from obesity-related health issues, a group that may include up to 3.4 million individuals in England. However, only those under the care of specialist weight management services will be able to use Mounjaro at first. This approach mirrors the introduction of Wegovy, another weight-loss drug offered in a similar phased rollout.
From June 2025, the NHS plans to expand access, but specific details regarding the full implementation remain unclear. GP practices are expected to play a key role in referring patients, but ongoing support, such as dietary guidance and monitoring, will likely require additional resources. NHS England is expected to release further details about these services in early 2025.
Cost and Effectiveness
Mounjaro is priced at £122 per patient per month for the maximum dose, but NICE has determined it to be cost-effective, given the high cost of obesity-related healthcare. Despite its promising results, concerns persist about the potential for weight gain after stopping the medication, highlighting the need for sustained support beyond the drug itself.
Wider Context and Global Considerations
While Wales and Scotland are also considering the drug’s use, reports indicate that the rollout in Scotland has faced challenges. Meanwhile, policymakers and healthcare providers around the world are closely monitoring the impact of such weight-loss medications, as obesity continues to be a significant public health issue.
Helen Kirrane from Diabetes UK acknowledged Mounjaro’s potential to help combat obesity, but expressed concern over the lengthy timeline for widespread access. Dr. Kath McCullough, NHS England’s national obesity adviser, emphasized that weight-loss medications are an essential part of addressing the obesity epidemic, which is one of the greatest public health challenges facing the NHS.
Looking Ahead
As the UK begins to introduce Mounjaro, it will be closely watched by other countries facing similar challenges related to obesity. The gradual rollout may offer vital lessons in balancing innovation with the practical realities of healthcare delivery. While the drug’s introduction marks a significant step forward in the fight against obesity, ensuring long- term success will require a comprehensive, multi-faceted approach involving support services and sustained patient engagement.
